Wednesday, June 24, 2026

Why China’s Top General Zhang Youxia Was Purged: Shocking Nuclear Secrets Leaked to the U.S.?

General Zhang Youxia, a top Chinese military official, was purged for allegedly leaking nuclear secrets to the U.S., not corruption.

Coupang Under Scrutiny: Why U.S. Investors Are Pushing Washington to Step In

Coupang's U.S. investors label South Korea's FTC investigation as retaliatory, urging U.S. intervention amid potential trade disputes.

Gold-Backed Financial Products See Massive Growth in South Korea Amid Price Surge

Gold prices surge amid global uncertainty, boosting interest in gold banking and sales in South Korea, with accounts increasing significantly.

Jin Joong Hwang

Author's Latest

CKDB-501A vs. Botox: Can CKD BiO’s New Botulinum Toxin Compete in China’s Booming Market?

Jongkundang Bio has successfully completed Phase 3 trials in China's botulinum toxin market, signaling global expansion.

How SK Bioscience Plans to Dominate the Global Vaccine Market in 2026

SK Bioscience enhances its operational system with new COO and key appointments to boost global competitiveness and vaccine development.

Botox Faces New Challenger: Chong Kun Dang’s Toxin Shows Non-Inferiority in China Study

Chong Kun Dang's CKDB-501A shows non-inferiority to Botox in Phase 3 trials for treating glabellar lines, with promising safety data.

NK Cell Cancer Therapies Move Closer to Market as Matica BioLabs Partners With Ingenium

CHA Biotech's Matica BioLabs partners with Ingenium Therapeutics for NK cell therapy production, targeting cancer treatment advancements.

ABL206: First-in-Class Dual Antibody Drug Conjugate Approved for Clinical Trials in the U.S. – What This Means for Cancer Treatment

ABL Bio and Neok Bio received FDA approval for ABL206, a dual-antibody ADC, marking a key milestone in their clinical development efforts.

K-Bio Revolution: How Korean Biopharmaceuticals Are Conquering the Global Market in 2026

South Korea's pharmaceutical industry thrives with innovative drugs like botulinum toxins and cancer treatments, targeting global markets.

Samsung Bioepis Secures U.S. Approval for Pen-Style Stelara Biosimilar, Setting a Market First

Samsung Bioepis receives FDA approval for Epyztek, the first pre-filled pen for autoimmune treatments, enhancing patient convenience.

Chong Kun Dang Wins European Phase 1 Approval for Dupixent Biosimilar: Advancing CKD-706’s Global Development

Chong Kun Dang's CKD-706 biosimilar for Dupixent received Phase 1 trial approval in Europe, aiming to expand treatment options for inflammatory diseases.

K-Bio Targets the U.S. Market: Celltrion and Samsung Bioepis Close in on Originator Drugs

Celltrion and Samsung Bioepis are expanding in the U.S. market, showing strong growth in biosimilars like Zymfentra and Hadlima.

How Ecrac Gel is Revolutionizing Axillary Hyperhidrosis Treatment in Korea: What You Need to Know

Dongwha Pharmaceutical launched Ecrac Gel, Korea's first prescription for underarm hyperhidrosis, promising effective relief for patients.

Unlocking Convenience: Rolvedon’s Same-Day Chemotherapy Solution for Neutropenia Revealed

Hanmi Pharmaceutical's Rolvedon shows potential for same-day chemotherapy administration, improving patient convenience and market competitiveness.

Is RPG-102 the Future of Obesity Treatment? Discover the Breakthrough Oral Solution!

ProGen and Rani Therapeutics initiate a Phase 1 trial for RPG-102, an oral obesity treatment, aiming for effective weight loss with weekly dosing.

HK inno.N’s New Drug K-CAB Applies for U.S. FDA Approval: How Innovative Is the P-CAB Therapy?

HK inno.N's K-Cap for GERD has entered the U.S. approval process, showing superior results in clinical trials over existing treatments.

How Neurophet AQUA is Transforming Dementia Diagnosis in South Korea: Key MOU Insights

Neurophet partners with Eisai Korea to enhance dementia screening and diagnostics using AI-based software, Neurophet AQUA.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.